Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 deaths/year by 2050, and the US will not be immune to such a catastrophe. Therefore the major growth opportunity for the infectious disease market lies in treating these antibiotic-resistant bacteria, in order to head oﬀ the impending global antibiotic resistance epidemic.
Worldwide deaths attributable to antibiotic
resistance versus other major causes of
death anticipated in 2050: